May 2 2012
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will
be presenting data from preclinical studies of its Toll-like receptor
(TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus
(SLE) and psoriasis, which suggest that IMO-8400 may be useful for the
treatment of both indications. The data from the SLE model will be
presented in an oral presentation at the American Association of
Immunologists (AAI) meeting in Boston, Massachusetts at 8:00a.m. ET on
May 5, 2012. The oral presentation, entitled "IMO-8400, a novel TLR7,
TLR8 and TLR9 antagonist, inhibits disease development in lupus-prone
NZBW/F1 mice," will be made during the session "Therapeutic Strategies
for Rheumatologic Diseases."
Idera expects to submit to the FDA an Investigational New Drug
application for IMO-8400 during the fourth quarter of 2012, and has
selected lupus as the initial disease indication for clinical
development.
In addition to the oral presentation, a poster presentation entitled
"IMO-8400, a novel TLR7, TLR8, and TLR9 antagonist, inhibits disease
development in mouse models of psoriasis" is scheduled for May 6, 2012,
in the session "Novel and Cellular Approaches to Autoimmunity" during
AAI.
Source: Idera Pharmaceuticals, Inc.
Vitiligo linked to increased risk of heart disease and stroke, study finds